within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AF11_Telbivudine;

model Telbivudine
  extends Pharmacolibrary.Drugs.ATC.J.J05AF11;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J05AF11</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Telbivudine is a synthetic thymidine nucleoside analogue with antiviral activity against hepatitis B virus (HBV). It is used as an oral antiviral agent for the treatment of chronic hepatitis B infection in adults with evidence of viral replication and active liver inflammation. Telbivudine has been withdrawn from the US market and is no longer widely used due to resistance concerns and the availability of better alternatives.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers, both male and female, following single and multiple oral doses.</p><h4>References</h4><ol><li><p>Zhou, XJ, et al., &amp; Brown, NA (2007). Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment. <i>Antimicrobial agents and chemotherapy</i> 51(12) 4231–4235. DOI:<a href=\"https://doi.org/10.1128/AAC.00557-07\">10.1128/AAC.00557-07</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17875994/\">https://pubmed.ncbi.nlm.nih.gov/17875994</a></p></li><li><p>Zhou, XJ, et al., &amp; Lai, CL (2006). Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications. <i>Antimicrobial agents and chemotherapy</i> 50(3) 874–879. DOI:<a href=\"https://doi.org/10.1128/AAC.50.3.874-879.2006\">10.1128/AAC.50.3.874-879.2006</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16495245/\">https://pubmed.ncbi.nlm.nih.gov/16495245</a></p></li><li><p>Zhou, XJ, et al., &amp; Brown, NA (2006). Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects. <i>Journal of clinical pharmacology</i> 46(3) 275–281. DOI:<a href=\"https://doi.org/10.1177/0091270005284849\">10.1177/0091270005284849</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16490803/\">https://pubmed.ncbi.nlm.nih.gov/16490803</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Telbivudine;
